Skip to main
EWTX

Edgewise Therapeutics (EWTX) Stock Forecast & Price Target

Edgewise Therapeutics (EWTX) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 63%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Edgewise Therapeutics is poised to disrupt the market for HCM treatment with its promising drug, securing funding for commercialization and an Outperform rating. While the company has sold its muscular dystrophy business, risks and challenges in securing funding and addressing potential side effects remain. The potential to reach a large, untreated patient population in the US makes this a potential lucrative investment.

Bears say

Edgewise Therapeutics is facing a negative outlook due to several fundamental reasons. The development and potential approval of its product candidates, including Sevasemten and EDG-7500, face challenges such as dose-limiting effects on heart function, which could require additional monitoring and potentially restrict the drug's use. Additionally, the company's financials may also be impacted by the need for further clinical trials and the potential for regulatory approval delays. Furthermore, while the company's drugs target a large market, they face competition from already approved treatments and future entrants in the muscular dystrophy and cardiac disease space.

Edgewise Therapeutics (EWTX) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 63% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edgewise Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edgewise Therapeutics (EWTX) Forecast

Analysts have given Edgewise Therapeutics (EWTX) a Buy based on their latest research and market trends.

According to 8 analysts, Edgewise Therapeutics (EWTX) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edgewise Therapeutics (EWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.